Abstract
Bortezomib, a small-molecule proteasome inhibitor, has activity in lung cancer both as a single agent and in combination with agents commonly used in lung cancer. The ability of bortezomib to favorably modulate the expression of apoptosis-associated proteins, along with its moderate toxicity as a single agent, provides the basis for its combination with cytotoxic agents in the treatment of lung cancer. In non-small cell lung cancer, bortezomib as a single agent has limited activity but in combination with chemotherapy has shown encouraging activity without significantly adding to toxicity. Bortezomibas a single agent has shown minimal activity in small cell lung cancer. Although the role of bortezomib in lung cancer is uncertain, it is likely to have its greatest clinical benefit when given in combination with other therapeutics. Ongoing studies are focused on optimizing the scheduling of bortezomib with chemotherapy, investigating its combination with targeted agents and radiation, and examining its efficacy in a specific subgroup, bronchioloalveolar carcinoma.
| Original language | English (US) |
|---|---|
| Journal | Clinical Cancer Research |
| Volume | 13 |
| Issue number | 15 |
| DOIs | |
| State | Published - Aug 1 2007 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Incorporating bortezomib into the treatment of lung cancer. / Davies, Angela M.; Lara, Primo N; Mack, Philip; Gandara, David R.
In: Clinical Cancer Research, Vol. 13, No. 15, 01.08.2007.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Incorporating bortezomib into the treatment of lung cancer
AU - Davies, Angela M.
AU - Lara, Primo N
AU - Mack, Philip
AU - Gandara, David R
PY - 2007/8/1
Y1 - 2007/8/1
N2 - Bortezomib, a small-molecule proteasome inhibitor, has activity in lung cancer both as a single agent and in combination with agents commonly used in lung cancer. The ability of bortezomib to favorably modulate the expression of apoptosis-associated proteins, along with its moderate toxicity as a single agent, provides the basis for its combination with cytotoxic agents in the treatment of lung cancer. In non-small cell lung cancer, bortezomib as a single agent has limited activity but in combination with chemotherapy has shown encouraging activity without significantly adding to toxicity. Bortezomibas a single agent has shown minimal activity in small cell lung cancer. Although the role of bortezomib in lung cancer is uncertain, it is likely to have its greatest clinical benefit when given in combination with other therapeutics. Ongoing studies are focused on optimizing the scheduling of bortezomib with chemotherapy, investigating its combination with targeted agents and radiation, and examining its efficacy in a specific subgroup, bronchioloalveolar carcinoma.
AB - Bortezomib, a small-molecule proteasome inhibitor, has activity in lung cancer both as a single agent and in combination with agents commonly used in lung cancer. The ability of bortezomib to favorably modulate the expression of apoptosis-associated proteins, along with its moderate toxicity as a single agent, provides the basis for its combination with cytotoxic agents in the treatment of lung cancer. In non-small cell lung cancer, bortezomib as a single agent has limited activity but in combination with chemotherapy has shown encouraging activity without significantly adding to toxicity. Bortezomibas a single agent has shown minimal activity in small cell lung cancer. Although the role of bortezomib in lung cancer is uncertain, it is likely to have its greatest clinical benefit when given in combination with other therapeutics. Ongoing studies are focused on optimizing the scheduling of bortezomib with chemotherapy, investigating its combination with targeted agents and radiation, and examining its efficacy in a specific subgroup, bronchioloalveolar carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=34547692973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547692973&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-07-0334
DO - 10.1158/1078-0432.CCR-07-0334
M3 - Article
C2 - 17671158
AN - SCOPUS:34547692973
VL - 13
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 15
ER -